摘要
目的探讨XP方案,卡培他滨(xeloda)、顺铂(CDDP)和FP方案,5-氟尿嘧啶(5-FU)、顺铂(CDDP),治疗晚期胃癌的疗效及安全性。方法选择115例符合条件的晚期胃癌患者,随机分为两组:治疗I组采用XP方案,口服卡培他滨(xeloda)1.0g,每日2次,d1～14;顺铂(CDDP)20mg/(m2·d),静脉滴注,d1～5,共1个疗程;治疗Ⅱ组采用FP方案:5-氟尿嘧啶(5-Fu)750mg/m2持续静脉滴注d1～5、顺铂(CDDP)20mg/(m2·d),静脉滴注,d1～5,共1个疗程。随访近期(21d,63d),远期(疗程结束后360d),观察两组患者的平均有效率(RR),总生存期(OS),无症状生存期(PFS)及主要不良反应的发生情况。结果治疗Ⅰ组(XP组)和治疗Ⅱ组(FP组)的有效率(RR)两组比较差异无统计学意义(P>0.05),总生存期(OS)、无症状生存期(PFS)两组对比无显著差异,而不良反应的发生率经比较治疗I组(XP组)明显低于治疗Ⅱ组(FP组),两组比较差异有统计学意义(P<0.05)。结论治疗I组(XP组)对于晚期胃癌患者不良反应较轻、并且临床使用方便,患者依从性好值得推广。
Objective To explore the efficacy and security of scheme XP(CDDP)and FP(5-Fu、CDDP)int reating the late gastric cancer.Methods 115 cases of gastric cancer were chosen and assigned to two therapy groups at random:Group 1 was administrated with scheme XP(Xeloda 1.0 twice a day d1～14 p.o、CDDP 20mg/(m 2 ·d)ivgtt d1～5,9 weeks).Group 2 was administrated with scheme FP(5-Fu 750mg/m 2 ivgtt d1-5、CDDP2 0mg/m 2 ·d ivgtt d1-5 9 weeks).RR,OS,PFS and side effects of two groups were observed during the 21d,63d and 360d following-up.Results Compare the RR of group 1 and 2(P>0.05),OS,PFS between these twog roups were no differences to0.But the incidence of side effect was significantly lower in group 1 than that in group 2(P<0.05).Conclusion Late gastric cancer therapy based on scheme XP was safer,more effective,more economical and convenient.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2010年第S1期39-40,共2页
Chinese Journal of Practical Internal Medicine
